Literature DB >> 18651118

[Secondary prevention after myocardial infarction].

J E Pflumm1, T Pomykaj, M P Heintzen.   

Abstract

A significant reduction in cardiovascular mortality has been achieved during the last decade. New techniques and materials for early coronary intervention have contributed significantly to reduce early mortality after myocardial infarction. Secondary prevention determines further progress; it combines evidence-based medical treatment as well as lifestyle modifications. ACE inhibitors, angiotensin receptor blockers, and beta-blocker positively affect elevated blood pressure, left ventricular remodeling, and electrical stability. Statins decrease LDL and increase HDL cholesterol. Acetylsalicylic acid and clopidogrel are indicated for antiplatelet therapy. Lifestyle modifications unite a diet rich in polyunsaturated fatty acids, moderate physical activity, weight reduction, and smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651118     DOI: 10.1007/s00108-008-2077-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  38 in total

Review 1.  Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.

Authors:  José López-Sendón; Karl Swedberg; John McMurray; Juan Tamargo; Aldo P Maggioni; Henry Dargie; Michal Tendera; Finn Waagstein; Jan Kjekshus; Philippe Lechat; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

2.  An overview of randomized trials of rehabilitation with exercise after myocardial infarction.

Authors:  G T O'Connor; J E Buring; S Yusuf; S Z Goldhaber; E M Olmstead; R S Paffenbarger; C H Hennekens
Journal:  Circulation       Date:  1989-08       Impact factor: 29.690

3.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

4.  Effect of the Italian smoking ban on population rates of acute coronary events.

Authors:  Giulia Cesaroni; Francesco Forastiere; Nera Agabiti; Pasquale Valente; Piergiorgio Zuccaro; Carlo A Perucci
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

5.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Authors:  M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

6.  Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.

Authors:  Catherine Demers; John J V McMurray; Karl Swedberg; Marc A Pfeffer; Christopher B Granger; Bertil Olofsson; Robert S McKelvie; Jan Ostergren; Eric L Michelson; Peter A Johansson; Duolao Wang; Salim Yusuf
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 8.  The efficacy and safety of exercise programs in cardiac rehabilitation.

Authors:  W L Haskell
Journal:  Med Sci Sports Exerc       Date:  1994-07       Impact factor: 5.411

9.  [Reduction of in-hospital mortality and improved secondary prevention after acute myocardial infarction. First results from the registry of secondary prevention after acute myocardial infarction (SAMI)].

Authors:  U Tebbe; C Messer; E Stammwitz; G S The; J Dietl; K-O Bischoff; U Schulten-Baumer; J Tebbenjohanns; H Gohlke; P Bramlage
Journal:  Dtsch Med Wochenschr       Date:  2007-07-30       Impact factor: 0.628

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more
  1 in total

1.  Potentially inappropriate medications in older Chinese outpatients based on the Beers criteria and Chinese criteria.

Authors:  Ying Zhang; Zhaoyan Chen; Fangyuan Tian
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.